Historically, invasive aspergillosis (IA) has been a major barrier for allogeneic hematopoietic stem cell transplantation (allo-HSCT). The influence of invasive IA on long-term survival and on transplant-related complications has not been investigated in a larger patient cohort under current conditions. Our aim was to analyze the long-term outcome of patients undergoing allo-HSCT with a history of prior IA. We used European Society for Blood and Marrow Transplantation database data of first allo-HSCTs performed between 2005 and 2010 in patients with acute leukemia. One thousand one hundred and fifty patients with data on IA before allo-HSCT were included in the analysis. The median follow-up time was 52.1 months. We found no significant impact of IA on major transplant outcome variables such as overall survival, relapse-free survival, non-relapse mortality, cumulative incidence of acute GvHD grade II-IV, chronic GvHD, pulmonary complications and leukemia relapse. However, we found a trend toward lower overall survival (P = 0.078, hazard ratio (HR) (95% confidence interval (CI)): 1.16 (0.98, 1.36)) and higher non-relapse mortality (P = 0.150, HR (95% CI): 1.19 (0.94, 1.50)) in allo-HSCT recipients with pre-existing IA. Our data suggest that a history of IA should not generally be a contraindication when considering the performance of allo-HSCT in patients with acute leukemia.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the most effective immunotherapy for cancer and is widely used. Every year more than 13 000 allo-HSCTs are performed in Europe, with acute leukemia being the main indication. Patients with acute leukemia are frequently diagnosed with invasive aspergillosis (IA) during induction therapy or post-remission therapy. In many of these patients, allo-HSCT is performed subsequently. As such, a considerable number of allo-HSCT recipients have a history of IA.
Previous studies have shown that IA may have a significant role in the clinical outcome of allo-HSCT. [1] [2] [3] [4] Although it has been generally accepted that prior IA may complicate an allo-HSCT, there is lack of data analyzing the outcome of allo-HSCT recipients with and without pre-existing IA. The absence of reliable data on the long-term impact of pre-existing IA on allo-HSCT outcome hampers evidence-based decision making on whether or not to perform an allo-HSCT. Therefore, it is not clear whether allo-HSCT recipients with pre-existing IA should be treated differently than allo-HSCT recipients without IA, for example, in respect to choosing the conditioning regimen, as well as the type and duration of immunosuppression.
Historically, pre-existing IA has been a contraindication for allo-HSCT. Nowadays, this is no longer the case, due to the availability of better tolerated antifungal agents and due to the emergence of less toxic conditioning regimens. In the 1990s, the first case series were published reporting on successful allo-HSCTs despite pre-existing IA. [3] [4] [5] More recent publications clearly demonstrate the feasibility of allo-HSCT in patients with a history of IA. 1, [6] [7] [8] In the present study, the Infectious Diseases and Acute Leukemia Working Parties of The European Society for Blood and Marrow Transplantation (EBMT) had the aim to analyze the long-term outcome of patients with acute leukemia undergoing allo-HSCT according to the presence-or absence of pre-existing IA.
MATERIALS AND METHODS

Eligibility criteria and data collection
Patient-, disease-and transplant-related variables were collected according to the data entries in the EBMT database. According to EBMT rules, patients gave informed consent for data entry into the EBMT registry database and for its use for analysis in accordance with the Declaration of Helsinki. The following eligibility criteria were used to select patients in the EBMT 1 database: children and adults with acute leukemia, who received a first allo-HSCT performed between 2005 and 2010. A total of 28 352 patients were identified of whom data on the existence of IA before allo-HSCT was available in 1150 patients; thus, the proportion of patients IA may not reflect the true prevalence. The reason that pre-existing IA was recorded in a subset of patients only is explained by the structure of the EBMT database. It is mandatory for every EBMT center to report patient history with a so-called MED-A (minimal essential data A) forms. These forms do Abbreviations: BM = bone marrow; CB = cord blood; D = donor; Prim Refr/no CR = Primary refractory/no complete remission; PB = peripheral blood; R = recipient; SCT = stem cell transplant.
not contain sufficient information to classify IA or no-IA. It is optional for EBMT centers to report patient history with MED-B forms, which contain more detailed information on history of fungal infections. We investigated the issue of missing values and generalization of results by means of several sensitivity analyses. In one traditional approach, all analyses were repeated on the whole population considering the missing value as another category. We also applied modern multiple imputation methods (Multivariate Imputation by Chained Equations, Package 'mice', R project). All results were confirmed in these analyses (data not shown). However, owing to the high percentage of missing data, the generalizability of the results cannot be verified.
In addition, the EBMT database does not contain data that allow distinguishing between the categories 'possible', 'probable' or 'proven' for prior IA.
Endpoints and statistical analysis
The primary endpoint was time of death. The median time of death from SCT was estimated using the Kaplan-Meier method. Death due to any cause was considered as an event. Patients alive at the end of the followup were censored at this date. Cohort 1 (with pre-existing IA) and Cohort 2 (without pre-existing IA) will be compared by the log-rank test. A Cox model was applied, in order to estimate the risk of dying for Cohort 1 and Cohort 2. The following variables entered the multivariate model as possible confounders: age (as continuous variable), gender (male vs female), underlying disease (ALL vs AML), status at SCT (first CR vs ⩾ 2 CR vs (Prim Refr/noCR)), time from diagnosis to SCT (as continuous variable), donor type (sibling vs matched unrelated donor (UD) vs mismatched unrelated donor vs Haplo), source of SCT (bone marrow vs peripheral blood vs cord blood), donor age, donor/recipient (d/r) gender match, donor/recipient CMV status, conditioning regimens (myeloablative conditioning (MAC) vs reduced intensity conditioning (RIC), TBI yes/no), type of immunosuppression (in vivo T depletion yes/no, in vitro T depletion yes/no).
Secondary endpoints. Non-relapse mortality, acute GvHD, chronic GvHD and relapse were the secondary endpoints. The cumulative incidences were computed using the cumulative incidence method. Differences between the two cohorts were verified with the Gray test. Maximum grade GvHD for each organ and maximum total GvHD grade were described.
Pulmonary complications were described by descriptive statistics.
RESULTS
Patients and transplant characteristics
The entry criteria for analysis of overall survival were fulfiled in 1150 patients. The main patients and transplant characteristics that were included in the analysis of overall survival are described in Table 1 . Most parameters were balanced between the two cohorts. However, a higher percentage of PB SCT, a lower percentage of bone marrow SCT, a higher percentage of ex vivo T-cell depletion and a higher percentage of reduced intensity conditioning were observed in the group of patients with a previous episode of IA. Data on the time between the last leukemia treatment and SCT were available in a subset of patients. We found no significant differences in the time to transplant between patients with pre-existing IA vs no pre-existing IA (Supplementary Table S1 ).
Survival endpoints
The median follow-up time was 52.1 months (95% confidence interval (CI): 49.0, 56.6). We found that the impact of prior IA on overall survival in allo-HSCT recipients with acute leukemia was not statistically significant (P = 0.078, hazard ratio (HR) (95% CI): 1.16 (0.98, 1.36); Figure 1a ). This result was confirmed when adjusting for confounders (Supplementary Table S2 ). The overall survival at 3 years and at 5 years was not significantly different in allo-HSCT recipients with pre-existing IA as compared with allo-HSCT recipients without a history of pre-existing IA ( Table 2) . As expected, we found several variables with significant impact on overall survival, such as stem cell source, remission status, donor type and donor age (Supplementary Table S2 ). Data are presented for two time points: after 3 years and 5 years.
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The impact of prior IA on non-relapse mortality in our study was not statistically significant (P = 0.150, HR (95% CI): 1.19 (0.94, 1.50); Figure 1b and Table 2 ). This result was confirmed when adjusting for confounders (Supplementary Table S3 ). We also found no significant impact of prior IA on relapse-free survival (Table 2) .
We detected no significant impact of the year of transplantation on overall survival: HR (95% CI): 0.98 (0.94, 1.03), P = 0.51; non-relapse mortality: HR (95% CI): 0.98 (0.91, 1.05), P = 0.50; and relapse-free survival: HR (95% CI): 1.00 (0.94, 1.06), P = 0.90.
Incidence of GvHD Next, we were interested in the impact of IA on acute GvHD. We detected no significant differences in the cumulative incidence of acute GvHD grade II-IV between the two cohorts (29.1% IA vs 32.0% no IA; P = 0.27, HR (95% CI): 0.89 (0.71, 1.10); Figure 2a ). This result was confirmed when adjusting for confounders (Supplementary Table S4 ). Furthermore, we found that there were no clinically meaningful differences in the severity of acute GvHD between the two cohorts ( Table 3) .
In patients that survived till day +100 or longer, we performed analyses on the incidence of chronic GvHD. Figure 2b demonstrates no statistical significant differences in the incidences of chronic GvHD between allo-HSCT recipients with or without pre-existing IA (43.9% IA vs 49.3% no IA; P = 0.26, HR (95% CI): 0.89 (0.73, 1.09)). This result was confirmed when adjusting for confounders (Supplementary Table S5 ). We found similar proportions of limited disease and extensive disease in the two cohorts (Table 3) .
Incidence of pulmonary complications Mortality and morbidity due to pulmonary complications has been a concern in allo-HSCT recipients with pre-existing pulmonary IA. Therefore, we were specifically interested in the incidence of non-infectious pulmonary complications, such as idiopathic pneumonia, ARDS (non-infectious), bronchiolitis obliterans, pulmonary fibrosis and lung hemorrhage. We found that the type and incidence of pulmonary complications were not different between allo-HSCT recipients with pre-existing IA vs no pre-existing IA (8.3% IA vs 6.9% no IA; P = 0.4, odds ratio (95% CI): 1.21 (0.77, 1.90); Supplementary Table S6 ).
Incidence of leukemia relapse IA may modulate post allo-HSCT immunity by direct interactions with the immune system or by influencing the management of pharmacological immunosuppression. We therefore analyzed the incidence of leukemia relapse after allo-HSCT in both cohorts. We found no difference in the incidence of acute leukemia relapse in allo-HSCT recipients with or without pre-existing IA (32.5% IA vs 32.5% no IA; P = 0.35, HR (95% CI): 1.11 (0.9, 1.36); Figure 3 ). This result was confirmed when adjusting for confounders (Supplementary Table S7 ). As expected, the disease status had a significant impact on relapse (Supplementary Table S7 Table S7) .
DISCUSSION
In the present study, we analyzed a large data set of patients with acute leukemia undergoing allo-HSCT between 2005 and 2010 in EBMT centers. We found a trend toward impaired outcome after Owing to missing data on acute GvHD, this analysis was performed on 1118 out of 1150 patients. The analysis on chronic GvHD was performed in patients that survived till day +100 or longer with available data.
allo-HSCT in patients with pre-existing IA. However, we detected no significant differences between patients with and without pre-existing IA under contemporary treatment conditions. Our findings differ from historic reports with smaller patient numbers, describing a major adverse impact of IA on allo-HSCT outcome. [3] [4] [5] 9 We believe that there are several factors that may have contributed to our results.
First, highly effective secondary antifungal prophylaxis may have led to improved outcome of allo-HSCT recipients with preexisting IA. It has been demonstrated in a controlled trial and in several case studies that secondary antifungal prophylaxis with voriconazole leads to considerably lower IA relapse rates as compared with those reported in historical controls. 6,9-11 These positive data led to a widespread use of secondary antifungal prophylaxis in allo-HSCT recipients and to reduced performance of surgical IA resections. 12 In the current study, the structure of the EBMT database did not allow us to investigate the choice of antifungal prophylaxis retrospectively. However, we assume that in the great majority of patients with pre-existing IA, a secondary antifungal prophylaxis was used and may have contributed to the nonsignificant differences in mortality between the two cohorts.
11,13-15 Accordingly, we were not able to provide data on posttransplant antifungal prophylaxis of individual patients. However, in line with current guidelines the standard primary antifungal prophylaxis was fluconazole in the majority of centers during the pre-engraftment period. [13] [14] [15] The primary anti-fungal prophylaxis after engraftment was not standardized and there was supposedly a great variety of management strategies in between the centers.
Second, an overall better supportive care management under current conditions may have improved specifically the outcome of allo-HSCT in patients with infectious complications including IA. This hypothesis is supported by recent publications from a French-Belgium study group, demonstrating that the outcome of severe infectious complications in patients with malignancies has considerably improved during the last decade and is mostly determined by the status of the underlying malignancy. 16, 17 However, in our study we detected no significant influences of the year of transplantation on survival endpoints during the study period.
Third, our analysis may have underestimated the effect of IA on allo-HSCT outcome because of the choice of our study population due to difficulties in diagnosing IA under 'real life conditions.' We were unable to assess the impact of the type of IA (proven/ probable vs possible) and the status of IA before allo-HSCT. Therefore, our analysis is not focussed exclusively on patients with 'probable' and 'proven' IA, but is rather a reflection of 'real life' in clinical allo-HSCT. In the contributing EBMT centers patients are often admitted for allo-HSCT, having been pre-treated for leukemia in other centers. It is common that there is a lack of high-quality microbiology data in these patients, for example, cultures or histology, and diagnosis of 'possible' IA is based on radiology and clinical aspects. 18 This leads to a possible bias, because we are unable to verify that some of the patients in the 'no IA group' had possible IA. Another effect of the lack of highquality microbiology data is the difficulty in distinguishing IA from other invasive mold infections. Therefore, we cannot exclude the possibility that some of the IA cases in our study were misdiagnosed cases of non-aspergillus mold infections. As a consequence, we cannot exclude the possibility that pre-existing 'proven/probable' IA has a higher adverse impact on allo-HSCT outcome than our data may suggest.
It is interesting to look at our data in the light of several recent publications showing that primary antifungal prophylaxis had no significant impact on survival in allo-HSCT recipients. Prophylaxis with voriconazole vs fluconazole was tested in a multicenter double-blind randomized controlled trial. 19 In this large study, the fungal-free survival after 6 months post allo-HSCT was not different between the study groups. In another multicenter trial, micafungin prevented invasive fungal infections but had no impact on survival, and as compared with fluconazole (a drug that has no efficacy against IA) in allo-HSCT recipients. 20 Posaconazole has been investigated in patients with acute GvHD, a patient population that is at extremely high risk of developing IA. 21 Despite the large cohort of 600 patients and a reduction of IA in the posaconazole arm, there was no difference in overall survival between the groups. 21 Taken together, results from several large clinical trials question the assumption that IA causes significant mortality in allo-HSCT recipients under current treatment conditions. Nevertheless, these studies showed significant decrement in the incidence of fungal infections, which may have reduced morbidity and resource utilization. In our study, we were unable to investigate the impact of pre-existing IA on resource utilization. Therefore, we cannot exclude a significant impact of pre-existing IA on such parameters, for example, duration of hospital stay.
Our data are exclusively from patients with acute leukemia undergoing allo-HSCT and our results may not fully apply to patients with other diseases undergoing allo-HSCT. However, our study adds further evidence to the hypothesis that better treatment in modern times has improved management of IA, leading to better outcome.
IA may have an impact on the incidence and severity of GvHD and on leukemia relapse rates, because it is a common strategy to reduce pharmacological immunosuppression, for example, with calcineurin inhibitors, in patients with IA earlier after HSCT. Another possible mechanism how IA may regulate GvHD and antitumor effects after allo-HSCT is the stimulation of immune mechanisms by Aspergillus species, which has been found in several allergic diseases including asthma and allergic bronchopulmonary aspergillosis. 22 Therefore, we specifically analyzed GvHD and found that allo-HSCT recipients with pre-existing IA had similar incidences of acute GvHD and chronic GvHD as compared with allo-HSCT recipients without pre-existing IA. In addition, we failed to detect significant differences in the incidence of leukemia relapse after allo-HSCT between the cohorts. Interestingly, we were able to again confirm previous findings demonstrating that the CMV serostatus influence leukemia relapse rates, suggesting that CMV may influence posttransplant immunity. 23, 24 Our results argue against a major effect of IA on GvHD or on anti-tumor effects after allo-HSCT. However, the registry data did not allow us to compare the type and duration of immunosuppression between the two cohorts. Figure 3 . Incidence of relapse. Data of 1150 allo-HSCT recipients with acute leukemia are shown. The incidence of leukemia relapse did not differ significantly between allo-HSCT recipients with pre-exisiting IA (blue line, n = 689) and allo-HSCT recipients without pre-exisiting IA (red line, n = 461; P = 0.35, HR (95% CI): 1.11 (0.9, 1.36)).
In conclusion, we found trends toward impaired outcome of allo-HSCT in patients with prior IA but we detected no significant impact on important allo-HSCT transplant outcomes, such as survival, GvHD and relapse. Our data suggest that a history of IA should not generally be considered a contraindication for allo-HSCT. To be able to more precisely investigate the impact of IA on allo-HSCT, we are currently planning a non-interventional prospective study.
